Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD study of meropenem in abdominal septic shock patients
ChiCTR2200063065Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of meropenem in septic shock and abdominal sepsis, sponsored by The First Hospital of Jilin University. Primary endpoint: Meropenem plasma concentration. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
meropenem
03
Conditions
septic shockabdominal sepsis
Beyond the preview
Go deeper on ChiCTR2200063065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063065.